Hint mode is switched on Switch off
For swift navigation between sections

Xcell Therapeutics

PDF download

Choose all Reset all
Download Cancel
Organization name
Xcell Therapeutics Inc
Country name
Republic of Korea
Country of registration
Republic of Korea
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Xcell Therapeutics Inc. operates as a pharmaceutical company. The Company researches, develops and manufactures xcell therapeutics, clonal selected mscs, automated mass cell culture, msc derived exosomes, and other related products. Xcell Therapeutics offers services throughout South Korea.

Awards

News

16/07/2024 Market Chatter: Xcell Therapeutics Shares Fall 4.7% Below Offering Price on Kosdaq Debut
All organization news

Documentation

Stocks

Public debt by currencies

Show more Hide

Codes

  • Business registration number
    534-86-00230
Registration is required to get access.